A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants with Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (GEMINI Gastric)

Principal Investigator

Elizabeth Smyth

Contact us

Email: orh-tr.earlyphasenurses@nhs.net

IRAS number

1006955